This is a preview of subscription content, log in via an institution to check access.
Notes
Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology
2015 US dollars
Reference
Shapiro CL, et al. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology : JCO2017737437, 12 Oct 2017. Available from: URL: http://doi.org/10.1200/JCO.2017.73.7437
Rights and permissions
About this article
Cite this article
Three-monthly zoledronic acid cost effective for bone metastases. PharmacoEcon Outcomes News 790, 32 (2017). https://doi.org/10.1007/s40274-017-4477-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4477-7